Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adams Q3

This article was originally published in The Tan Sheet

Executive Summary

Adams Respiratory Therapeutics will institute a 4% price increase for its Mucinex franchise effective July 1, the firm announces during a third-quarter earnings call May 11. Strong market penetration by the brand drove sales for the quarter up 29% to $76 mil., with the entire brand contributing $74.8 mil., the company reports. Net sales of single-ingredient Mucinex (600 mg guaifenesin) grew 20% to $51.9 mil. and sales of Mucinex DM (600 mg guaifenesin/30 mg dextromethorphan) rose 28% to $18.3 mil. Mucinex D (600 mg guaifenesin/60 mg pseudoephedrine), which launched in late October 2005, recorded net sales of $4.7 mil. Adams will allot $50 mil. in ad spend to support a new line of Mucinex pediatric products that are expected to launch in 2006. Separately, the firm will add 25 new representatives to its existing 100-person field force; the new employees are expected to be hired, trained and deployed by July 15...

Topics

UsernamePublicRestriction

Register

PS099357

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel